Corcept Therapeutics Incorporated

Merck reported second-quarter revenues of $16.61 billion, up 5.1% year on year and 2.1% above analysts' expectations, as the nine branded pharmaceuticals stocks tracked by the report collectively beat consensus revenue estimates by 6.6%. The company beat analysts' EPS estimates but missed analysts' full-year EPS guidance estimates, and its stock is up 16.2% since reporting, trading at $148.50. Among peers, Corcept Therapeutics posted the group's best quarter with revenues of $256.1 million, up 31.7% year on year and 21.6% above expectations, while Zoetis delivered the weakest performance with revenues of $2.47 billion, flat year on year and 1.5% below expectations. Collegium Pharmaceutical reported revenues of $199.9 million, up 6.3% year on year but 0.7% below expectations, and Pfizer reported revenues of $15.03 billion, up 2.6% year on year and 4.4% above expectations. As a group, share prices of the tracked companies have held steady, up 2.1% on average since the latest earnings results.

Supernus Pharmaceuticals reported second-quarter revenues of $211.3 million, up 27.7% year on year and exceeding analysts' expectations by 2.8%, as the broader group of 9 branded pharmaceuticals stocks tracked reported a strong quarter with revenues beating consensus estimates by 6.6% as a group. The company said full-year operating income guidance exceeded analysts' expectations and full-year revenue guidance slightly topped them, prompting President and CEO Jack Khattar to cite the continued strength and sustained momentum of its growth products and continued execution on its commercial strategy. Despite the beat, Supernus shares are down 5.9% since reporting and currently trade at $41.99. Among peers, Bristol-Myers Squibb reported revenues of $12.97 billion, up 5.7% year on year and 12.9% above expectations, while Corcept Therapeutics posted revenues of $256.1 million, up 31.7% and 21.6% above estimates, the biggest beat and highest full-year guidance raise of the group. Zoetis delivered the weakest performance, with revenues of $2.47 billion, flat year on year and 1.5% below expectations, alongside a significant miss of full-year EPS guidance estimates.

Corcept Therapeutics raised its full-year 2026 revenue guidance to $1.10-$1.20 billion from an earlier expectation of $950 million to $1.05 billion, reflecting growing momentum in its lead marketed drug Korlym and other business activities. Korlym, approved for the treatment of Cushing's syndrome, recorded sales of $373.5 million in the first six months of 2026, up 6.2% year over year, and remains the majority driver of the company's top line. The company is working to diversify beyond Korlym, and in March 2026 the FDA approved Lifyorli, or relacorilant, in combination with nab-paclitaxel for adults with platinum-resistant ovarian cancer; Lifyorli generated $47.6 million in the second quarter of 2026, its first quarter of commercial availability. Corcept resubmitted its new drug application for relacorilant in hypercortisolism in June 2026, and the FDA accepted the application with a target action date of Dec. 17, 2026. The Zacks Consensus Estimate for 2026 earnings per share has risen from 58 cents to $2.02 over the past 60 days, while the 2027 estimate has increased from $2.27 to $3.44.

Corcept Therapeutics reported second-quarter revenues of $256.1 million, up 31.7% year on year and beating analysts' expectations by 21.6%, making it the standout performer among eight branded pharmaceutical stocks tracked. The company also beat EPS estimates and raised full-year revenue guidance above expectations, with its stock up 28.1% since reporting to trade at $119.05. Bristol-Myers Squibb posted revenues of $12.97 billion, up 5.7% and 12.9% above estimates, while Eli Lilly delivered the fastest revenue growth at 47.7% to $22.97 billion, beating by 11.4%. Zoetis was the weakest, with flat revenues of $2.47 billion missing estimates by 1.5% and lowering full-year guidance. Supernus Pharmaceuticals reported $211.3 million in revenue, up 27.7% and 2.8% above estimates.

Glucotrack, Bausch Health, and Corcept Therapeutics were among Thursday's top biotech gainers, driven by pipeline progress and strong financial results. Glucotrack's subsidiary Lokahi Therapeutics advanced development of LT-100, a non-narcotic therapy derived from honeybee venom, with plans to begin clinical evaluation of a simplified single-injection method as early as the fourth quarter of 2026, sending shares up 173.68% to $0.78. Bausch Health raised its full-year 2026 revenue outlook to between $10.790 billion and $11.040 billion after reporting second-quarter consolidated revenue of $2.85 billion, a 13% increase, and its stock rose 28.85% to $6.03. Corcept Therapeutics posted second-quarter net income of $43.0 million on revenue of $256.1 million, including $208.6 million from Korlym and its authorized generic and $47.6 million from newly launched Lifyorli, and lifted its 2026 revenue forecast to $1.1 billion to $1.2 billion, pushing shares up 27.29% to $118.32. Nuwellis surged 135.45% to $4.45 after a study on its Aquadex therapy was accepted by a peer-reviewed journal, while Neogen touched a 52-week high of $11.56 and closed up 22.26% at $11.53 following its fiscal 2026 results and fiscal 2027 guidance.

Corcept Therapeutics reported first-quarter revenues of $164.9 million, a 4.9% year-on-year increase that fell 11.3% short of analyst expectations, yet its stock has surged 107% since the announcement to trade at $96.50. The company, which focuses on cortisol-modulating medications, achieved the highest full-year guidance raise among the ten branded pharmaceuticals stocks tracked but also had the weakest performance against analyst estimates. The broader group posted mixed results, with aggregate revenues beating consensus by 3.6% and share prices rising an average of 8.5% since reporting. Eli Lilly delivered the strongest quarter, with revenues of $19.8 billion up 55.5% year on year and a 13.7% beat, while Zoetis was the weakest, missing estimates and seeing its stock fall 31.7%.

Several biotech stocks reached 52-week highs on July 24, 2026, driven by upcoming quarterly reports and regulatory milestones. Inhibikase Therapeutics hit $2.53 after its lead candidate IKT-001 received FDA Orphan Drug designation for pulmonary arterial hypertension, with a global Phase 3 trial underway. Jazz Pharmaceuticals reached $256.75, supported by 19% first-quarter revenue growth to $1.1 billion and progress with Zanidatamab in breast cancer studies. Halozyme Therapeutics climbed to $82.99 following a 42% year-over-year revenue increase to $376 million in the first quarter and full-year guidance of $1.71 billion to $1.81 billion. Corcept Therapeutics touched $97.63, with first-quarter revenue rising to $164 million from $157 million a year earlier, ahead of its July 29 earnings report. Liquidia Corporation hit $91.10, buoyed by $130 million in first-quarter YUTREPIA sales and a net income of $52 million.

Corcept Therapeutics CFO Mokari Atabak sold 40,000 shares on July 15, 2026, in a transaction valued at $3.5 million, according to an SEC filing. The sale was executed through a cashless exercise of options at $19.26 and $23.06 per share, with all resulting shares sold at a weighted average price of $87.71. The transaction was conducted under a Rule 10b5-1 trading plan adopted on December 12, 2025, the same month the stock lost half its value in a single session before more than doubling by the sale date. Following the sale, Atabak directly holds 16,130 shares, but his total economic exposure remains substantial through nearly 180,000 derivative securities. Corcept, a specialty pharmaceutical company with a market capitalization of $9.6 billion, saw its stock recover after FDA approval of relacorilant for ovarian cancer, now sold as Lifyorli, and raised full-year revenue guidance to as much as $1.05 billion.

Corcept Therapeutics Chief Development Officer William Guyer sold 20,000 shares on July 7, 2026, realizing $1.9 million in gross proceeds at a weighted average price of $93.13 per share. The transaction was a cashless exercise of 20,000 options at a strike price of $21.65 followed by an immediate open-market sale, executed under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following the sale, Guyer directly holds 3,985 common shares, of which 1,599 are unvested restricted stock awards, while retaining 130,000 derivative securities in the form of stock options. The sale occurred against a backdrop of positive company developments, including the early FDA approval of Lifyorli for ovarian cancer and raised full-year revenue guidance to between $950 million and $1.05 billion, though first-quarter results showed a $31.8 million loss due to launch spending.

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, or $85.00 per share in all cash, sending Crinetics shares up 99% this week. The deal, unanimously approved by both boards and expected to close in Q3 2026, gives Vertex Crinetics' endocrine franchise, including the approved acromegaly treatment PALSONIFY and the Phase 3 candidate atumelnant for congenital adrenal hyperplasia and Cushing's syndrome. Vertex projects the acquired assets could deliver over $5 billion in peak annual sales and contribute earnings accretion by 2029. The acquisition also lifted shares of endocrine rare-disease peers, with Neurocrine Biosciences gaining 6.24%, Corcept Therapeutics rising 5.04%, and Ascendis Pharma adding 3.51%, as investors repriced potential M&A targets. Crinetics stock is trading just under the $85 cash offer, capping upside unless a competing bid emerges.

Corcept Therapeutics has resubmitted its new drug application for relacorilant to the FDA as a treatment for Cushing's syndrome. The company expects a six-month review period and included additional data analyses requested by the FDA after a complete response letter in December 2025. The resubmission is supported by positive results from the GRACE study, the phase III GRADIENT study, and long-term extension data. Corcept shares have soared 134.9% year to date, while the industry has declined 9.1%.